Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $61
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept's Potential in IgA Nephropathy
Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Vera Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $71
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $61
Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $100
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
TD Cowen Remains a Buy on Vera Therapeutics (VERA)